Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Macrophage-Engineered Vesicles...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization

Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization

Bibliographic Details
Main Authors: Khaga R. Neupane, J. Robert McCorkle, Timothy J. Kopper, Jourdan E. Lakes, Surya P. Aryal, Masud Abdullah, Aaron A. Snell, John C. Gensel, Jill Kolesar, Christopher I. Richards
Format: Article
Language:English
Published: American Chemical Society 2021-01-01
Series:ACS Omega
Online Access:https://doi.org/10.1021/acsomega.0c05632
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1021/acsomega.0c05632

Similar Items

  • Human macrophage-engineered vesicles for utilization in ovarian cancer treatment
    by: David Schweer, et al.
    Published: (2023-01-01)
  • Cell-Derived Vesicles for in Vitro and in Vivo Targeted Therapeutic Delivery
    by: Aaron A. Snell, et al.
    Published: (2019-07-01)
  • Single-Molecule Studies of Membrane Receptors from Brain Region Specific Nanovesicles
    by: Surya Aryal, et al.
    Published: (2021-05-01)
  • Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
    by: David Schweer, et al.
    Published: (2021-01-01)
  • Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
    by: Brian T. Burgess, et al.
    Published: (2020-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs